Medicaid

Pharmalot

Pharmalot

Ohio Medicaid examines a curious PBM relationship. Do other states have a similar issue?

By Ed Silverman

AmerisourceBergen

Pharmalot

AmerisourceBergen pays $625 million to settle allegations of illegally distributing drugs

By Ed Silverman

advertisement

Gilead

Pharmalot

Looking to bolster dwindling hepatitis C sales, Gilead plans to sell generic versions

By Ed Silverman

advertisement

Pfizer Allergan

Pharmalot

Doctor claims hospital fired him for complaining about ‘unethical’ ties to Allergan

By Ed Silverman

Abilify-MyCite illustration

Pharma

At $1,650 per month, the first digital pill will soon roll out to certain Medicaid patients with mental illness

By Rebecca Robbins

Pharmacy Benefit Managers illustration

Politics

The Trump administration can’t decide whether drug industry middlemen are the enemy — or part of the solution

By Ike Swetlitz

Pharmalot

Pharmalittle: More turnover at Gilead Sciences; EMA scales back its transparency policy

By Ed Silverman

advertisement

Laura Dolph

Politics

Tapered to zero: In radical move, Oregon’s Medicaid program weighs cutting off chronic pain patients from opioids

advertisement

CVS/Aetna

Pharmalot

Ohio Medicaid cancels contracts with two big PBMs over ‘spread’ pricing

By Ed Silverman

Charlie Baker

Pharmalot

To lower state drug costs, the National Governors Association is promoting several ideas

By Ed Silverman

HHS Secretary Alex Azar

Politics

HHS takes aim at drug companies for an ‘abusive behavior’ in Medicaid

By Ike Swetlitz

Hepatitis C

Pharmalot

Louisiana explores a ‘Netflix’ subscription model for buying hepatitis C drugs

By Ed Silverman

Pharmalot

AstraZeneca to pay $110 million to Texas for defrauding Medicaid and illegally marketing drugs

By Ed Silverman

An UBER application is shown as cars drive by.

First Opinion

Curtailing Medicaid’s transportation benefit is ‘penny-wise and pound-foolish’

By Michael Adelberg, Patricia Salber, and Michael Cohen

Pharmalot

Pharmalittle: CVS and Ohio battle over Medicaid data; AbbVie strikes another Humira biosimilar deal

By Ed Silverman

Pharmalot

Pharmalittle: CMS drops plan for Novartis drug; lawsuit offers fresh details on Purdue opioid marketing

By Ed Silverman

Pharmalot

Pharmalittle: Takeda bid for Shire passes first shareholder test; Amazon agrees to buy PillPack

By Ed Silverman

Generic medication

Politics

Mass. gets a thumbs-down on negotiating Medicaid prices, but Oklahoma wins on ‘value’ rebates

By Erin Mershon

Sarepta - hearing

Politics

Medicaid must pay for drugs approved through FDA’s ‘accelerated’ pathway, agency tells states

By Ike Swetlitz

Medicaid

Pharmalot

Ohio peels back the curtain on a lucrative PBM profit center

By Ed Silverman

Hospital medicaid

First Opinion

An insider’s view of the myths and misconceptions behind 340B ‘reform’

By Bradford R. Lang

Prison

Pharmalot

Can a federal drug discount program unlock savings for state prisons?

By Ed Silverman

Seema Verma

Politics

Which drug makers’ medicines are racking up bigger and bigger bills for Medicare and Medicaid?

By Erin Mershon

Rep. Peter Welch

Pharmalot

Lawmakers introduce bill to fine drug makers for incorrect Medicaid classifications

By Ed Silverman

Boston Children’s Hospital

First Opinion

Medicaid’s unnecessary barriers delay care for children with complex needs

By Nick Manetto, Joshua Greenberg, and Mathieu Gaulin

Amazon Berkshire JPM Health Care

Business

Bill Gates is glad Amazon is getting into health care — but cautions it’s complicated

By Megan Thielking

Pharmalot

Pharmalittle: Has ‘right to try’ legislation stalled? Probes into copay charities are slowing contributions

By Ed Silverman

Vertex Pharmaceuticals Inc. building

Pharmalot

New York panel votes to lower the cost of a pricey Vertex drug for cystic fibrosis

By Ed Silverman

Pharmalot

Pharmalot

How a patient advocacy group is used to promote an Insys drug and other fentanyl meds

By Ed Silverman